Published in J Exp Med on November 02, 1998
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest (2008) 3.14
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (1999) 2.94
Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med (2005) 2.22
B16 as a mouse model for human melanoma. Curr Protoc Immunol (2001) 1.80
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest (2003) 1.70
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest (2006) 1.59
Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med (2001) 1.57
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57
Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes. PLoS One (2010) 1.49
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol (2000) 1.47
Retracted CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection. Cancer Res (2009) 1.41
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest (2004) 1.30
Immune recognition of self in immunity against cancer. J Clin Invest (2004) 1.27
Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol (2005) 1.27
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 1.22
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. Cancer Res (1999) 1.10
Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res (2009) 1.09
Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 1.08
Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. ACS Nano (2011) 1.04
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res (2010) 0.90
Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant (2015) 0.89
Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids. Proc Natl Acad Sci U S A (2011) 0.87
Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res (2008) 0.86
Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens. Vaccine (2010) 0.85
Mechanisms of immunization against cancer using chimeric antigens. Mol Ther (2008) 0.85
Carbon nanotubes as vaccine scaffolds. Adv Drug Deliv Rev (2013) 0.84
Immune rejection of mouse tumors expressing mutated self. Cancer Res (2009) 0.84
Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood (2006) 0.83
Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models. J Transl Med (2010) 0.83
Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. J Immunol (2012) 0.83
Prevention of cytotoxic T cell escape using a heteroclitic subdominant viral T cell determinant. PLoS Pathog (2008) 0.82
Cross-reactive cytotoxic T lymphocytes against human immunodeficiency virus type 1 protease and gamma interferon-inducible protein 30. J Virol (2005) 0.81
Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells. Cancer Immunol Immunother (2010) 0.81
Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol (2015) 0.81
Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology (2014) 0.80
Cross-reactivity of T cells and its role in the immune system. Crit Rev Immunol (2012) 0.80
Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy (2014) 0.78
Structural and functional correlates of enhanced antiviral immunity generated by heteroclitic CD8 T cell epitopes. J Immunol (2014) 0.78
Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses. J Immunol (2011) 0.78
Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas. Br J Cancer (2005) 0.77
Enhanced responses to tumor immunization following total body irradiation are time-dependent. PLoS One (2013) 0.77
Development of effective vaccines for old mice in a tumor model. Vaccine (2008) 0.77
Enhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic Peptides. Front Immunol (2015) 0.77
Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. Ann Transl Med (2016) 0.75
Flanking residues are central to DO11.10 T cell hybridoma stimulation by ovalbumin 323-339. PLoS One (2012) 0.75
Overview on poly(ADP-ribose) immuno-biomedicine and future prospects. Proc Jpn Acad Ser B Phys Biol Sci (2016) 0.75
Intraperitoneal immunotherapy: historical perspectives and modern therapy. Cancer Gene Ther (2016) 0.75
Progress in cancer vaccines by enhanced self-presentation. Proc Natl Acad Sci U S A (2001) 0.75
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma. Oncoimmunology (2017) 0.75
A cell culture model for T lymphocyte clonal anergy. Science (1990) 9.86
A theory of self-nonself discrimination. Science (1970) 7.99
Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature (1996) 6.20
An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science (1996) 5.93
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Peptides naturally presented by MHC class I molecules. Annu Rev Immunol (1993) 4.66
The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol (1995) 4.60
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med (1985) 3.86
Negative selection of lymphocytes. Cell (1994) 3.47
Cloning and expression of cDNA encoding mouse tyrosinase. Nucleic Acids Res (1986) 3.21
Cancer antigens: immune recognition of self and altered self. J Exp Med (1994) 2.97
Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol (1988) 2.48
The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med (1990) 2.44
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13
Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol (1996) 2.11
Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A (1996) 1.85
Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med (1991) 1.77
Human tumor antigens recognized by T cells. Curr Opin Immunol (1996) 1.54
CD4-independent in vivo priming of murine CTL by optimal MHC class I-restricted peptides derived from intracellular pathogens. Int Immunol (1995) 1.19
A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res (1996) 1.15
The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition. J Immunol (1993) 1.12
MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. J Immunol (1994) 1.02
Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int J Cancer (1997) 1.01
Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res (1997) 0.91
T cell receptor (TCR) recognition of MHC class I variants: intermolecular second-site reversion provides evidence for peptide/MHC conformational variation. J Exp Med (1996) 0.88
Molecular analysis of a heteroclitic T cell response to the immunodominant epitope of sperm whale myoglobin. Implications for peptide partial agonists. J Immunol (1995) 0.85
Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology (1995) 0.84
The specificity of positive selection: MHC and peptides. Immunol Rev (1993) 0.83
Recognition of autoantigens by patients with melanoma. Ann N Y Acad Sci (1993) 0.82
Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg (2000) 13.24
Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A (1980) 7.33
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum (1980) 3.87
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer (1999) 2.90
Community health worker performance in the management of multiple childhood illnesses: Siaya District, Kenya, 1997-2001. Am J Public Health (2001) 2.64
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53
Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A (1998) 2.50
The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med (1990) 2.44
Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med (2000) 2.25
Quantitative in situ hybridization of ribosomal RNA species to polytene chromosomes of Drosophila melanogaster. J Mol Biol (1977) 2.18
Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Localization of a unique gene by direct hybridization in situ. Proc Natl Acad Sci U S A (1981) 2.13
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06
Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer (1999) 2.03
Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 2.02
Surgical management of intra-abdominal desmoid tumours. Br J Surg (2000) 2.01
Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med (1989) 1.98
Distribution of kinetochore (centromere) antigen in mammalian cell nuclei. J Cell Biol (1981) 1.97
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86
Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer (2001) 1.86
Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A (1996) 1.85
Expanded CD4+ and CD8+ T cell clones in elderly humans. J Immunol (1997) 1.84
Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol (2000) 1.83
Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J Exp Med (1984) 1.81
Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. Cancer (2000) 1.78
Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol (1997) 1.77
Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. J Cell Biol (1995) 1.76
Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol (1997) 1.75
Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A (1983) 1.71
Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest (1997) 1.69
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 1.63
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine (2005) 1.59
Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. Proc Natl Acad Sci U S A (1982) 1.59
Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58
Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer (2000) 1.58
A human autosomal phosphoglycerate kinase locus maps near the HLA cluster. Proc Natl Acad Sci U S A (1984) 1.55
Allelic variations in the human T cell receptor V beta 6.7 gene products. J Exp Med (1990) 1.55
Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer (1993) 1.52
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J Exp Med (1983) 1.48
Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med (1984) 1.48
The effect of age on the B-cell repertoire. J Clin Immunol (2000) 1.47
Extraskeletal osteosarcoma: analysis of outcome of a rare neoplasm. Sarcoma (2000) 1.42
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. Proc Natl Acad Sci U S A (1985) 1.39
Isolation and characterization of a complementary DNA expressing human U1 small nuclear ribonucleoprotein C polypeptide. J Immunol (1988) 1.37
Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg (2001) 1.36
Evaluation of Elispot assays: influence of method and operator on variability of results. J Immunol Methods (2004) 1.36
CD8+CD28- T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev (2001) 1.34
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol (1988) 1.34
A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med (1999) 1.33
Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development. Immunol Rev (1997) 1.32
Is there a role for incomplete resection in the management of retroperitoneal liposarcomas? J Am Coll Surg (2001) 1.32
Cytological mapping of the human glucose-6-phosphate dehydrogenase gene distal to the fragile-X site suggests a high rate of meiotic recombination across this site. Proc Natl Acad Sci U S A (1984) 1.30
Soft tissue tumors of the abdominal wall: analysis of disease patterns and treatment. Arch Surg (2001) 1.29
Age-related dysregulation in CD8 T cell homeostasis: kinetics of a diversity loss. J Immunol (2000) 1.29
Glucose-induced inhibition of in vitro bone mineralization. Bone (2001) 1.28
Antinuclear antibodies in localized scleroderma. Arthritis Rheum (1983) 1.27
Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors. Cancer (1998) 1.27
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci U S A (2000) 1.26
The scattered distribution of actin genes in the mouse and human genomes. EMBO J (1982) 1.26
Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome. J Exp Med (1995) 1.25
Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res (1985) 1.24
Confirmed angiosarcoma: prognostic factors and outcome in 50 prospectively followed patients. Sarcoma (2000) 1.24
Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer (1999) 1.21
Detection of a sub-set of polysomal mRNAs associated with modulation of hypusine formation at the G1-S boundary. Proposal of a role for eIF-5A in onset of DNA replication. FEBS Lett (1995) 1.21
Evidence against Ha-ras-1 involvement in sporadic and familial melanoma. Nature (1987) 1.21
Epithelioid sarcoma: clinical behavior and prognostic factors of survival. Ann Surg Oncol (1997) 1.20
Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer (2000) 1.20
Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys (2000) 1.20
CD4-independent in vivo priming of murine CTL by optimal MHC class I-restricted peptides derived from intracellular pathogens. Int Immunol (1995) 1.19
Cloning of cDNA encoding steroid 11 beta-hydroxylase (P450c11). Proc Natl Acad Sci U S A (1987) 1.17
Close linkage of random DNA fragments from Xq 21.3-22 to X-linked agammaglobulinaemia (XLA). Hum Genet (1987) 1.16
A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res (1996) 1.15
Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery (2000) 1.15
A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med (1993) 1.13
A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol (1999) 1.12
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer (1992) 1.12
Transient myopia with severe chemosis associated with exacerbation of disease activity in systemic lupus erythematosus. J Rheumatol (1992) 1.11
T cell antigen receptors in autoimmunity. J Immunol (1988) 1.11
Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol (2001) 1.11
Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer (2000) 1.10
Definition of tumor antigens suitable for vaccine construction. Semin Cancer Biol (1995) 1.10
Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. Cancer Res (1987) 1.09
Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer (1998) 1.09
The human genes for hemophilia A and hemophilia B flank the X chromosome fragile site at Xq27.3. EMBO J (1985) 1.09
The majority of postselection CD4+ single-positive thymocytes requires the thymus to produce long-lived, functional T cells. J Exp Med (1995) 1.09
The localization of the genes coding for histone H4 in human chromosomes. Cold Spring Harb Symp Quant Biol (1978) 1.08
Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis. Activation-induced death can occur without Fas receptor. J Immunol (1996) 1.08